insights_auto
Why is DMYD-B up 6.86%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
SEK 1.09
arrow_upward
+6.86%(+0.070) 1D
Oct 16, 5:30:00 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEK 1.00
High
SEK 1.09
Low
SEK 0.99
Mkt. cap
165.11M
Avg. vol.
842.57K
Volume
0.00
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.76
Shares outstanding
134.00M
No. of employees
42
Open
SEK 1.00
High
SEK 1.09
Low
SEK 0.99
Mkt. cap
165.11M
Avg. vol.
842.57K
Volume
0.00
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.76
Shares outstanding
134.00M
No. of employees
42
News stories
From web sources and news partners
Opening Bell Daily
·
1 hour ago
Stock market after midterms: S&P 500 up all 19 times
FinanceFeeds
·
1 hour ago
The Nasdaq Index Just Had Its Worst Week Since June - and Netflix, Tesla and Meta Report Next
Yahoo Finance
·
11 hours ago
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
MarketWatch
·
1 day ago
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB